Menu
Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. HF10 therapy has demonstrated the ability to reduce or eliminate opioids in =65% of patients across six peer-reviewed clinical studies. The Senza® System, Senza II™ System, and the Senza® Omnia™ System are the only SCS systems that deliver Nevro's proprietary HF10® therapy. Senza, Senza II, Senza Omnia, HF10, Nevro and the Nevro logo are trademarks of Nevro Corp.
1800 Bridge Pkwy
Redwood City, California 94065-1164
Phone: 16502510005
www.nevro.com
Friday, March 24, 2023 at 2:00 pm Eastern Time REDWOOD CITY, Calif., Feb. 23, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced that D. Keith Grossman,…
Medical device company Nevro (NVRO) hit a 52-week low of $33.36 on Wednesday. Over the last year, the stock is down ~49%.
Nevro Corp. (NYSE:NVRO) marked $39.51 per share on Thursday, up from a previous closing price of $38.33. While Nevro Corp. has overperformed by 3.08%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NVRO fell by -45.91%, with highs and lows ranging from $78.90 to $34.70, whereas […]
Nevro Corp (NYSE: NVRO ) reported Q4 FY22 sales of $113.8 million , up 11% Y/Y as reported and 12% constant currency, beating the consensus of $113.40 million. Painful diabetic neuropathy (PDN) indication sales of approximately $17.3 million grew 329%, bringing the first full-year sales to approximately $48.0 million. Q4 FY22 U.S. trial procedures increased by 9%, while U.S. PDN trial procedures grew to 20% of total U.S. trials in the quarter. Guidance: Nevro expects Q1 FY23 sales of $94-$96 million vs. the consensus of $97.51 million. PDN indication Q1 sales … Full story available on Benzinga.com
Nevro Corporation (NYSE:NYSE:NVRO) Q4 2022 Earnings Conference Call February 16, 2023 4:30 PM ETCompany ParticipantsJulie Dewey - Chief Corporate Communications and Investor Relations…
REDWOOD CITY, Calif. (AP) — REDWOOD CITY, Calif. (AP) — Nevro Corp. (NVRO) on Thursday reported a loss of $19.2…
Nevro press release (NVRO): Q4 GAAP EPS of -$0.54 misses by $0.05.Revenue of $113.84M (+10.8% Y/Y) beats by $0.14M.Provides First Quarter 2023 Revenue Guidance of $94 Million to…
REDWOOD CITY, Calif., Feb. 16, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of chronic pain, today announced its fourth quarter and full-year 2022 financial results. The company…
Nevro (NYSE: NVRO ) is set to give its latest quarterly earnings report on Thursday, 2023-02-16. Here''s what investors need to know before the announcement. Analysts estimate that Nevro will report an earnings per share (EPS) of $-0.49. Nevro bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next … Full story available on Benzinga.com
Nevro Corp. has seen multiple boom-bust cycles in its share price, and we are in the bust phase again. Does this mean NVRO stock is a buy? Read to find out.
The share price of Nevro Corp. (NYSE:NVRO) fell to $37.35 per share on Wednesday from $38.58. While Nevro Corp. has underperformed by -3.19%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, NVRO fell by -42.39%, with highs and lows ranging from $78.90 to $34.70, whereas the […]
Leading Indicator Aimed at Increasing Transparency Surrounding Gender-Related Practices and Policies REDWOOD CITY, Calif., Jan. 31, 2023 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is delivering comprehensive, life-changing solutions for the treatment of…
